(Q38113498)

29 August 2017

Newer treatments in the management of pediatric asthma (English)

1 reference

29 August 2017

1 reference

1

1 reference

29 August 2017

Peter Van Asperen

2

1 reference

29 August 2017

1 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

15

1 reference

29 August 2017

4

1 reference

29 August 2017

291-302

1 reference

https://scigraph.springernature.com/pub.10.1007/s40272-013-0020-x

29 August 2017

0 references

cites work

Progressive airflow limitation is a feature of children with severe asthma.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Progression of asthma measured by lung function in the childhood asthma management program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Alveolarization continues during childhood and adolescence: new evidence from helium-3 magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

New therapies for asthma: is there any progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Severe asthma: advances in current management and future therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Advances in pediatric asthma in 2010: addressing the major issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

International consensus on (ICON) pediatric asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

The functional benefit of anti-inflammatory aerosols in the lung periphery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Ventilation heterogeneity in children with well controlled asthma with normal spirometry indicates residual airways disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Omalizumab improves asthma-related quality of life in children with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Tiotropium Respimat increases the risk of mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Adherence and asthma control with mometasone furoate versus fluticasone propionate in adolescents and young adults with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Mometasone furoate in children with mild to moderate persistent asthma: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Once-daily ciclesonide in children: efficacy and safety in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Pharmacology and therapeutics of bronchodilators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Glucocorticosteroids: current and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Prevention by theophylline of beta-2-receptor down regulation in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Low-dose theophylline in childhood asthma: a placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Doxofylline: The next generation methylxanthine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Macrolides in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Clarithromycin targets neutrophilic airway inflammation in refractory asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Evaluation of blood vessels and edema in the airways of asthma patients: regulation with clarithromycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Cytokine/anti-cytokine therapy - novel treatments for asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

TH17 cells in asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Untangling the complex web of IL-4- and IL-13-mediated signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Lebrikizumab treatment in adults with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Asthma phenotypes and interleukin-13--moving closer to personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Mepolizumab and exacerbations of refractory eosinophilic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Effect of vitamin D and inhaled corticosteroid treatment on lung function in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Relationship between serum vitamin D, disease severity, and airway remodeling in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Vitamin D and glucocorticoids differentially modulate chemokine expression in human airway smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

The rising cost of vitamin D testing in Australia: time to establish guidelines for testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Is hypovitaminosis D a consequence rather than cause of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Patterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

The prevalence of nonadherence in difficult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

"Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Relationship of adherence to pediatric asthma morbidity among inner-city children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Overcoming barriers to nonadherence in asthma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Dry powder inhalers: which factors determine the frequency of handling errors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Medication use in children with asthma: not a child size problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

The role of viruses in acute exacerbations of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Do early-life viral infections cause asthma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Leukotriene A(4) hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

5-Oxo-ETE and the OXE receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Effect of suplatast tosilate on antileukotriene non-responders with mild-to-moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Reslizumab for Poorly Controlled, Eosinophilic Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Evidence of a role of tumor necrosis factor alpha in refractory asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Tiotropium bromide step-up therapy for adults with uncontrolled asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Selective PDE inhibitors as novel treatments for respiratory diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Evaluation of atorvastatin for the treatment of patients with asthma: a double-blind randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Association between antenatal cytokine production and the development of atopy and asthma at age 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

New and future developments of therapy for asthma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0020-X

A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children

21 January 2018

1 reference

12 December 2020

Two novel, severe asthma phenotypes identified during childhood using a clustering approach

1 reference

12 December 2020

Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma

1 reference

12 December 2020

Inflammation of small airways in asthma

1 reference

12 December 2020

Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma

1 reference

12 December 2020

Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase

1 reference

12 December 2020

Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies

1 reference

12 December 2020

IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist

1 reference

12 December 2020

Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis.

1 reference

12 December 2020

Asthma and wheezing in the first six years of life. The Group Health Medical Associates

1 reference

12 December 2020

Prevention of asthma during the first 5 years of life: A randomized controlled trial

1 reference

12 December 2020

Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma

1 reference

12 December 2020

Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma

1 reference

12 December 2020

Relationship between the benefits of suplatast tosilate, a Th2 cytokine inhibitor, and gene polymorphisms in children with bronchial asthma

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma

1 reference

12 December 2020

Is the best offense a good D-fense? Should we use vitamin D as adjunctive therapy for asthma?

1 reference

12 December 2020

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment

1 reference

12 December 2020

Omalizumab: NICE to USE you, to LOSE you NICE

1 reference

12 December 2020

Mild to moderate asthma affects lung growth in children and adolescents

1 reference

12 December 2020

Long-term monotherapy with suplatast tosilate in patients with mild atopic asthma: a pilot comparison with low-dose inhaled fluticasone

1 reference

12 December 2020

A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma

1 reference

12 December 2020

Anti-IgE for asthma in inner-city children.

1 reference

12 December 2020

Oral xanthines as maintenance treatment for asthma in children

1 reference

12 December 2020

Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma

1 reference

12 December 2020

A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma

1 reference

12 December 2020

Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report

1 reference

12 December 2020

Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers

1 reference

12 December 2020

Lebrikizumab treatment in adults with asthma

1 reference

12 December 2020

Eight-year outcomes of the Childhood Asthma Prevention Study

1 reference

12 December 2020

Long-term inhaled corticosteroids in preschool children at high risk for asthma

1 reference

12 December 2020

Erythromycin treatment in diffuse panbronchiolitis

1 reference

12 December 2020

Symptom-pattern phenotype and pulmonary function in preschool wheezers

1 reference

12 December 2020

Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children

1 reference

12 December 2020

Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism

1 reference

12 December 2020

Noncompliance and treatment failure in children with asthma

1 reference

12 December 2020

Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study

1 reference

12 December 2020

Alveolar tissue inflammation in asthma

1 reference

12 December 2020

10.1007/S40272-013-0020-X

Identifiers

DOI

1 reference

PubMed ID

23754138

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23754138